864 Intravenous (IV) vinorelbine (VRL) plus hormone therapy (HT) versus hormone therapy alone in hormone-refractory prostate cancer (HRPC). Final report of a randomised phase III study — Raymond P. Abratt (2003) | RDL Network
864 Intravenous (IV) vinorelbine (VRL) plus hormone therapy (HT) versus hormone therapy alone in hormone-refractory prostate cancer (HRPC). Final report of a randomised phase III study
Sikander Ailawadhi, Ivan Špıčka, Andrew Spencer, Jin Lu, Albert Oriol, Silvia Ling, Fredrik Schjesvold, Alejandro Berkovits, Marek Hus, Chunrui Li, Meletios A Dimopoulos, Péter Rajnics, Sevgi Kalayoğlu Beşışık, Vânia Hungria, Maria Del Rosario Custidiano, Gurdeep Parmar, Xavier Leleu, Fei Li, Claudio Cerchione, César Cinesi Gómez, Tadao Ishida,
Meletios A Dimopoulos, Christos Kiamouris, Dimitra Gika, Charalambos Deliveliotis, A. Giannopoulos, Anastasios Zervas, Christos Alamanis, C. Constantinidis, Michael Koutsilieris
Sikander Ailawadhi, Ivan Špıčka, Andrew Spencer, Jin Lu, Albert Oriol, Silvia Ling, Fredrik Schjesvold, Alejandro Berkovits, Marek Hus, Chunrui Li, Meletios A Dimopoulos, Péter Rajnics, Sevgi Kalayoğlu Beşışık, Vânia Hungria, Maria Del Rosario Custidiano, Gurdeep Parmar, Xavier Leleu, Fei Li, Claudio Cerchione, César Cinesi Gómez, Tadao Ishida,
Discussion(0)
No comments yet. Be the first to comment.